Exhibit 99.1

				One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com
News Release

AMGEN’S SECOND QUARTER 2014 REVENUES INCREASED 11

PERCENT TO $5.2 BILLION AND ADJUSTED EARNINGS PER

SHARE (EPS) INCREASED 25 PERCENT TO $2.37

Second Quarter 2014 GAAP EPS Were $2.01

2014 Total Revenues and Adjusted EPS Guidance Increased to $19.5-$19.7 Billion and $8.20-$8.40, Respectively

Reallocating Resources to Drive Growth

THOUSAND OAKS, Calif. (July 29, 2014) – Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2014. Key results include:

“Robust growth through the first half of 2014 affirms the underlying strength of our business,” said Robert A. Bradway, chairman & chief executive officer. “We are making excellent progress in advancing our pipeline as we prepare to launch a number of promising new innovative medicines. From a position of strength, we have announced today restructuring initiatives that will allow us to reallocate resources to invest in our upcoming launches and drive growth.”

References in this release to “adjusted” measures, measures presented “on an adjusted basis” or to free cash flow refer to non-GAAP financial measures. These adjustments and other items are presented on the attached reconciliations.

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 2

Product Sales Performance

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 3

Product Sales Detail by Product and Geographic Region

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 4

Operating Expense and Tax Rate Analysis, on an Adjusted Basis

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 5

Cash Flow and Balance Sheet Discussion

Note: Numbers may not add due to rounding

Reallocating Resources to Drive Growth

“The talented staff members at these locations have made enormous contributions to advancing biotechnology over the years and the surrounding communities have been very supportive, so it is with great reluctance that we acknowledge the need to exit,” continued Bradway. “At each site, we are actively engaging in discussions with third-parties about potential future use of the facilities.”

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 6

2014 Guidance

For the full year 2014, the Company expects:

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 7

Second Quarter Product and Pipeline Update

Projected 2014 milestones for innovative pivotal programs:

Evolocumab

Ivabradine

Kyprolis

Talimogene laherparepvec

Blinatumomab

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 8

Vectibix

Trebananib

Brodalumab

AMG 416 (formerly known as velcalcetide)

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 9

Non-GAAP Financial Measures

In this news release, management has presented its operating results for the second quarters of 2014 and 2013 in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on an adjusted (or non-GAAP) basis. In addition, management has presented its full year 2014 EPS and tax rate guidance in accordance with GAAP and on an adjusted (or non-GAAP) basis. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, cost-savings initiatives and certain other items from the related GAAP financial measures. Management has also presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the second quarters of 2014 and 2013. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP. Reconciliations for these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the news release.

The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor’s overall understanding of the financial performance and prospects for the future of the Company’s core business activities by facilitating comparisons of results of core business operations among current, past and future periods. In addition, the Company believes that excluding the non-cash amortization of intangible assets, including developed product technology rights, acquired in business combinations treats those assets as if the Company had developed them internally in the past, and thus provides a supplemental measure of profitability in which the Company’s acquired intellectual property is treated in a comparable manner to its internally developed intellectual property. The Company believes that FCF provides a further measure of the Company’s liquidity.

The Company uses the non-GAAP financial measures set forth in the news release in connection with its own budgeting and financial planning. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

Amgen Webcast

As previously announced, Amgen will hold a conference call to discuss these results and the matters described in this news release today, July 29, 2014, at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen’s senior management team. Slides further detailing these results and the matters to be discussed in the webcast are now available on Amgen’s website, www.amgen.com, under Investors.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website under Investors. Information regarding webcast presentation times, webcast availability, webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 10

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2013, and in any subsequent periodic reports on Form 10-Q and Form 8-K. Words such as “expect,” “anticipate,” “outlook,” “could,” “target,” “project,” “intend,” “plan,” “believe,” “seek,” “estimate,” “should,” “may,” “assume,” or “continue,” and variations of such words and similar expressions are intended to identify such forward looking statements. Reference is made in particular to forward-looking statements regarding product sales, revenue, expenses, earnings per share, tax rates, clinical trial results, regulatory filings and actions, Company strategy, restructuring charges, staff reductions and facility closures/dispositions and trends. We are providing this information as of the date of this news release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign), and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others’ regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Our efforts to integrate the operations of companies we have acquired may not be successful. Cost saving initiatives may result in us incurring impairment or other related charges on our assets. We may experience difficulties, delays or unexpected costs and not achieve anticipated cost savings from our recently announced restructuring plans. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 11

###

CONTACT: Amgen, Thousand Oaks

David Caouette, 805-447-2661 (media)

Arvind Sood, 805-447-1060 (investors)

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 12

Amgen Inc.

Condensed Consolidated Statements of Income - GAAP

(In millions, except per share data)

(Unaudited)

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 13

Amgen Inc.

Condensed Consolidated Balance Sheets - GAAP

(In millions)

(Unaudited)

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 14

Amgen Inc.

GAAP to Adjusted Reconciliations

(In millions)

(Unaudited)

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 15

Amgen Inc.

GAAP to Adjusted Reconciliations

(In millions, except per share data)

(Unaudited)

The following table presents the computations for GAAP and Adjusted diluted EPS. Dilutive securities used to compute Adjusted diluted EPS were computed assuming that we do not expense stock options.

Second Quarter 2014 Revenues Increased 11 Percent to $5.2 Billion and Adjusted Earnings Per Share Increased 25 Percent to $2.37

Page 16

Amgen Inc.

Reconciliations of Free Cash Flow

(In millions)

(Unaudited)

Reconciliation of GAAP EPS Guidance to Adjusted

EPS Guidance for the Year Ending December 31, 2014

(Unaudited)

Reconciliation of GAAP Tax Rate Guidance to Adjusted

Tax Rate Guidance for the Year Ending December 31, 2014

(Unaudited)